PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA CONTAINING FLT3 INHIBITOR AND MDM2 INHIBITOR

Provided are: a pharmaceutical composition for treating acute myeloid leukemia (AML), the pharmaceutical composition containing a therapeutically effective combination of an FMS-like tyrosine kinase-3 (FLT3) inhibitor, a pharmaceutically acceptable salt thereof, or a solvate thereof, and a murine double minute 2 (MDM2) inhibitor, a pharmaceutically acceptable salt thereof, or a solvate thereof; and a method for treating acute myeloid leukemia using same. L'invention concerne : une composition pharmaceutique pour le traitement De la leucémie aiguë myéloïde (LAM), la composition pharmaceutique contenant une combinaison thérapeutiquement efficace d'un inhibiteur de la tyrosine kinase-3 de type FMS (FLT-3), d'un sel pharmaceutiquement acceptable de celui-ci ou d'un solvate de celui-ci, et d'un inhibiteur double de murine double minute 2 (MDM2), d'un sel pharmaceutiquement acceptable de celui-ci ou d'un solvate de celui-ci ; et un procédé de traitement de la leucémie aiguë myéloïde mettant en œuvre ladite composition. Fms-유사 티로신 키나아제(Fms-like tyrosine kinase-3: FLT3) 저해제, 이의 약제학적으로 허용되는 염, 또는 이의 용매화물과, 뮤린 더블 미닛 2(Murine double minute 2: MDM2) 저해제, 이의 약제학적으로 허용되는 염, 또는 이의 용매화물을 치료적 유효한 조합으로 포함하는, 급성 골수성 백혈병(AML) 치료용 약학적 조성물 및 이를 이용한 급성 골수성 백혈병의 치료 방법을 제공한다.